SSA Swiss Advisors AG Increases Stock Holdings in Pfizer Inc. $PFE

Key Points

• SSA Swiss Advisors AG increased its stake in Pfizer Inc. by 13.4% during the 2nd quarter, holding 126,369 shares valued at approximately $3.2 million.
• Analysts have set a consensus rating of "Hold" for Pfizer, with the average price target at $28.13, while several firms have adjusted their ratings and price objectives recently.
• Pfizer announced a quarterly dividend of $0.43 per share, representing a yield of 6.9%, with an ex-dividend date set for November 7th.

SSA Swiss Advisors AG lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 126,369 shares of the biopharmaceutical company's stock after buying an additional 14,900 shares during the quarter. SSA Swiss Advisors AG's holdings in Pfizer were worth $3,197,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Focus Partners Advisor Solutions LLC raised its holdings in shares of Pfizer by 3.2% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 149,257 shares of the biopharmaceutical company's stock valued at $3,618,000 after buying an additional 4,686 shares during the period. Curio Wealth LLC raised its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,098 shares during the period. Keeler Thomas Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $2,408,000. Boothe Investment Group Inc. increased its holdings in Pfizer by 17.0% during the 2nd quarter. Boothe Investment Group Inc. now owns 324,557 shares of the biopharmaceutical company's stock worth $7,867,000 after purchasing an additional 47,261 shares during the last quarter. Finally, Leelyn Smith LLC increased its holdings in Pfizer by 6.1% during the 2nd quarter. Leelyn Smith LLC now owns 99,337 shares of the biopharmaceutical company's stock worth $2,408,000 after purchasing an additional 5,729 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PFE shares. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday, October 10th. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. UBS Group restated a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $28.13.

Pfizer Trading Up 0.5%

NYSE:PFE opened at $24.79 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.17. The firm has a market capitalization of $140.92 billion, a P/E ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a 50 day simple moving average of $24.87 and a 200 day simple moving average of $24.17.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer's payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.